Sarcoma, oo ku dhacda dadka da'da yar waana buro halis ah oo ka timaadda unugyada mesenchymal (oo ay ku jiraan unugyada isku xidhka iyo muruqa). Sarcomasku aad bay u xun yihiin oo si degdeg ah ayay u kobcaan! Sarcomasyada caadiga ah waxaa ka mid ah osteosarcoma, leiomyosarcoma, lymphosarcoma, iyo sarcoma synovial. Leiomyoma, lymphosarcoma, iyo sarcoma synovial ayaa laga yaabaa inay yeeshaan metastases dhiig marxalad hore.
The preferred method of sarcoma is surgery. In order to seek a radical cure, domestic doctors usually require patients to have their limbs amputated. However, it is currently difficult to treat unresectable or advanced liposarcoma and leiomyosarcoma that occur behind the peritoneum and have large tumors. Hospitals at home and abroad tend to retain most of the limbs and then perform radiotherapy.
Sarcoma is not sensitive to chemotherapy drugs! The efficiency of local radiotherapy is also poor, but once the lung metastases are less effective.
Palbociclib capsule is a highly selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. It is also the first breast cancer immunotherapy inhibitor to be approved by the US FDA. Palbociclib capsules are targeted drugs for the treatment of sarcoma.
Sida Palbociclib u shaqeeyo: Dhammaan unugyada nool waxay maraan qayb unug, iyo Palbociclib wuxuu si wax ku ool ah u horjoogsan karaa geedi socodka qaybinta unugyada, iyo isku-darka Palbociclib daawooyinka kale ee kansarka ka-hortagga sida daaweynta endocrine, chemotherapy, iyo daaweynta kale ee la beegsanayo ayaa daaweyn kara noocyo badan oo kansar ah saamaynta bogsashada.
Daaweynta la beegsanayo waxay isticmaali kartaa daawooyin kala duwan iyo waxqabadyo kale si ay si sax ah u aqoonsadaan una weeraraan unugyada kansarka iyaga oo aan waxyeello u geysan unugyada caadiga ah. Dr. Peter J. O'Dwyer ayaa sheegay in marka lagu daro neutrophils, Palbociclib uu leeyahay Saameynta unugyada sidoo kale waa yar tahay, dawaduna waxay si wax ku ool ah u hor istaagi kartaa koritaanka burooyinka burooyinka. Markaan ogaanno shaqooyinka cusub ee bartilmaameedka CDK4 / 6, waxaa laga yaabaa inaan horumarinno isku-darka dawooyinka cusub sida wakiillada ka-hortagga kansarka.
According to the research results and early clinical trial results published by scientists at the University of Pennsylvania in the journal JAMA Oncology, the results of phase 2 clinical trials of 29 sarcoma patients show that the drug Palbociclib can achieve a median progression-free survival of 66% of patients 12 weeks. Palbociclib is effective in the treatment of sarcoma and can prolong the progression-free survival of patients.
